Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LINKER-MM3: linvoseltamab versus elotuzumab + pomalidomide + dexamethasone in relapsed/refractory multiple myeloma
2022-501396-62-00Phase 3Authorised
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 17
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Linvoseltamab with Elotuzumab + pomalidomide + dexamethasone (2 arms). Primary endpoint: Progression-free survival in CD38 antibody exposed participants. Planned start Sep 2023; status: authorised.
02
Drugs
linvoseltamabelotuzumabpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2022-501396-62-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501396-62-00.